Hepatocellular carcinoma
Conditions
Interventions
Donafenib group:Donafenib
Sponsors
Hu'nan Provincial Tumor Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years (including 75 years old), no gender limit; 2. Pathological diagnosis of hepatocellular carcinoma, and radical resection was performed 4-8 weeks before enrollment; 3. CNLC stage Ia-IIa, postoperative pathological detection of patients with microvascular invasion (MVI); 4. No recurrence or metastasis was confirmed by imaging examination >=4 weeks after operation; 5. Child-Pugh grading of liver function is 3 months; 8. HBV DNA = 104 copies/ml, antiviral treatment should be given first, and then enter the study until the HBV DNA drops below 104 copies/ml. And continue to take antiviral drugs and monitor liver function and hepatitis B viral load; 9. All HCV RNA-positive patients should receive antiviral treatment, and then enter the study if they are negative.
Exclusion criteria
Exclusion criteria: 1. Positive margins; 2. Reoperation for recurrent liver cancer; 3. Tumor rupture; 4. A single tumor larger than 8cm; 5. Preoperative imaging or intraoperative macroscopic observation found that the subject had portal vein tumor thrombus, or inferior vena cava tumor thrombus, hepatic vein tumor thrombus or bile duct tumor thrombus, lymph node invasion or extrahepatic metastasis; 6. Suffering from other malignant tumors within 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year cumulative recurrence-free survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| recurrence-free survival;overall survival;tumor recurrence time;safety; | — |
Countries
China
Contacts
Public ContactLuo Jia
Hu'nan Provincial Tumor Hospital
Outcome results
None listed